Review of antiretroviral agents for the treatment of HIV infection

Stanic, Anela; Grana, Julie C.
February 2009
Formulary;Feb2009, Vol. 44 Issue 2, p47
Academic Journal
Research into the treatment of HIV infection has resulted in the development of 5 antiretroviral (ARV) drug classes: entry inhibitors, including fusion inhibitors and chemokine coreceptor (CCR) inhibitors; nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs); non-nucleoside reverse transcriptase inhibitors (NNRTIs); integrase inhibitors; and protease inhibitors (PIs). With the approval of the first PIs, the treatment of HIV shifted to highly active ARV therapy (HAART). HAART, which refers to a combination of agents from ≥2 different ARV classes, is a standard approach for treating HIV infection today. The challenge of controlling HIV in patients with resistance to ARVs has contributed to accelerated research into treatments with novel ARV activity. This research has led to the introduction of a CCR5 inhibitor, an integrase inhibitor, and a new NNRTI. This article provides a review of recently approved and investigational agents for the treatment of HIV-1 infection in adult patients, as well as an overview of ARV treatment guidelines. (Formulary. 2009;44;47-54.)


Related Articles

  • Survival of HIV-Infected Injection Drug Users (IDUs) in the Highly Active Antiretroviral Therapy Era, Relative to Sex- and Age-Specific Survival of HIV-Uninfected IDUs. Muga, Roberto; Langohr, Klaus; Tor, Jordi; Sanvisens, Arantza; Serra, Isabel; Rey-Joly, Celestino; Muñoz, Álvaro // Clinical Infectious Diseases;8/1/2007, Vol. 45 Issue 3, p370 

    Background. In the era of highly active antiretroviral therapy (HAART), it remains unclear whether human immunodeficiency virus (HIV)—infected injection drug users (IDUs) have durations of survival similar to those for comparable HIV-uninfected IDUs. The goal of this study was to compare...

  • Raltegravir. Croxtall, Jamie D.; Scott, Lesley J. // Drugs;2010, Vol. 70 Issue 5, p631 

    Raltegravir, a first-in-class, oral HIV type-1 (HIV-1) integrase inhibitor, blocks the covalent integration of HIV-1 complementary DNA into the host genome. In a large, randomized, double-blind, multinational, ongoing trial in treatment-naive patients with HIV-1 infection, raltegravir 400?mg...

  • Immune Reconstitution Inflammatory Syndrome. Tappuni, A.R. // Advances in Dental Research;Apr2011, Vol. 23 Issue 1, p90 

    Immune reconstitution inflammatory syndrome (IRIS) is a phenomenon observed in patients recovering from immunodeficiency. The clinical presentation of IRIS involves the unmasking of covert infections or the worsening of overt conditions. Several causes and pathways have been suggested, most...

  • A taxonomy for community-based care programs focused on HIV/AIDS prevention, treatment, and care in resource-poor settings. Rachlis, Beth; Sodhi, Sumeet; Burciul, Barry; Orbinski, James; Cheng, Amy H.Y.; Cole, Donald // Global Health Action;2013, Vol. 6 Issue 1, p1 

    Community-based care (CBC) can increase access to key services for people affected by HIV/AIDS through the mobilization of community interests and resources and their integration with formal health structures. Yet, the lack of a systematic framework for analysis of CBC focused on HIV/AIDS...

  • People with AIDS (PWA) Since Highly Active Antiretroviral Therapy, 1996. Dunbar, Deanne // Journal of Medical Humanities;Jun2011, Vol. 32 Issue 2, p115 

    lthough clarity about HIV transmission biology and effective therapy should mean that an AIDS diagnosis is more socially acceptable today, for some groups the cultural stigma of HIV infection has changed little in the last 30 years. This paper will examine why representations of HIV-positive gay...

  • Antiretroviral Therapy as HIV Prevention: Status and Prospects. Mayer, Kenneth H.; Venkatesh, Kartik K. // American Journal of Public Health;Oct2010, Vol. 100 Issue 10, p1867 

    As antiretroviral treatment of HIV infection has become increasingly accessible, attention has focused on whether these drugs can used for prevention because of increased tolerability of newer medications, decreased cost, and the limitations of other approaches. We review the status of...

  • Clinical Management of Treatment- Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era. Boyd, Mark A.; Hill, Andrew M. // PharmacoEconomics;2010 Supplement, Vol. 28, p17 

    Despite the success of combination antiretroviral therapy (ART) in improving clinical outcomes, treatment failure remains a significant challenge, particularly for highly treatment-experienced patients. This review evaluates current issues in the management of HIV-infected, treatment-experienced...

  • Healthcare utilization of patients accessing an African national treatment program. Harling, Guy; Orrell, Catherine; Wood, Robin // BMC Health Services Research;2007, Vol. 7, p80 

    Background: The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when...

  • Metabolic and Skeletal Complications of HIV Infection. Morse, Caryn G.; Kovacs, Joseph A. // JAMA: Journal of the American Medical Association;8/16/2006, Vol. 296 Issue 7, p844 

    Over the past 10 years, in conjunction with the broad availability of potent antiretroviral regimens, the care of human immunodeficiency virus (HIV)-infected patients has shifted from prevention and treatment of opportunistic infections and malignancies to management of the metabolic and related...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics